If you think the £0.9m milestone is nailed on think again.
Tim is on record stating if they don’t fix the solubility issue they may continue with it anyway, what’s the betting this happens and no £0.9m milestone payment is received………
“A further payment of approximately £0.9 million will be payable to Sareum if certain milestones related to the oral bioavailability of the Compounds are achieved within nine months from the date of the Agreement”
For years now the Bod have been sharing our TYK2 data with all and sundry in the industry and they are still not licensed, everyone is aware of the compounds there’s no hidden agenda here. Is our SDC-1801 really the best in class where’s the data to back this up as investors we really are investing blind and we have more and more competition appearing on the scene the most concerning being TLL018 and it’s close to finishing P1. Losing the £4 million milestone has put us In a very weak position, the Bod have some serious financial decisions to make to push a P1 next year, if they do decide to raise its going to be big so hopefully they will give us plenty of data to make an informed investment decision at that juncture.
Good News! Also the Oxford Vaccine could be ready by this Christmas can be stored at fridge temperature, produces an immune response in both young and old adults and is 10 times cheaper than Pfizer's.
https://www.dailymail.co.uk/news/article-8950453/Hopes-British-Covid-vaccine-Christmas.html
TLL Pharma’s TLL018 is not behind ours Nick in fact it is some 18 months ahead it finished pre-clinical last year and is about to finish its P1 in Healthy Participants. What Tim was saying is there is very little data to compare against SDC-1801
https://clinicaltrials.gov/ct2/show/NCT04243083
TLL018 seems to have a much better IC50 value when compared to SDC-1801 and as such could prove to be a serious competitor